Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00985036
NCT00985036WithdrawnNot Applicable

Is VEGF a Useful Serum Biomarker for Patients Diagnosed With Meningioma or Glioma?

Marquette General Health System1 site in 1 countryStarted: September 2009Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Withdrawn
Locations
1
Primary Endpoint
Determine if VEGF levels correlate with tumor progression or recurrence
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Objectives: This study is looking at the level of vascular endothelial growth factor (VEGF) circulating in the blood stream of patients diagnosed with either a meningioma or a glioma. The questions that will be addressed include:

  1. Can VEGF level alert us to tumor progression or recurrence before MRI changes occur?
  2. Is the VEGF level an indicator of the response to treatment?
  3. Does the VEGF level correlate with tumor histology and behavior?
  4. Is there a relationship between VEGF level and outcome?

Study Design

Study Type
Observational
Observational Model
Case Control
Time Perspective
Prospective

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •any patient presenting with glioma or meningioma

Exclusion Criteria

  • •a different type of brain tumor

Outcomes

Primary Outcomes

Determine if VEGF levels correlate with tumor progression or recurrence

Time Frame: every one to three months

Secondary Outcomes

  • Determine if the VEGF level is an indicator of the response to treatment.(Every one to three months)
  • Determine if the VEGF level correlates with tumor histology and behavior.(Every one to three months)
  • Determine if there is a relationship between VEGF level and outcome.(Every one to three months)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Richard A. Rovin, MD FACS

Neurosurgeon

Marquette General Health System

Study Sites (1)

Loading locations...

Similar Trials

Completed
Not Applicable
Are Serum Levels of Vascular Endothelial Growth Factor a Marker for the Early Diagnosis of Ectopic Pregnancy?Ectopic Pregnancy
NCT01261026Federal University of São Paulo
Completed
Not Applicable
Serum VEGF as a Tubal Pregnancy MarkerPregnancy, Ectopic
NCT02973230University of Sao Paulo General Hospital90
Completed
Not Applicable
Vascular Endothelial Growth Factor (VEGF), Platelet Derived Growth Factor (PDGF), Hepatocyte Growth Factor (HGF) in Patients With Acute Coronary Syndrome (ACS)Acute Coronary Syndrome
NCT00844987National Institute of Cardiology, Warsaw, Poland120
Completed
Not Applicable
EG-VEGF : Potential Marker of Pre-eclampsia and / or Intrauterine Growth RestrictionIntra-uterine Growth RetardationPre-eclampsia
NCT01490489Institut National de la Santé Et de la Recherche Médicale, France142
Completed
Not Applicable
An Investigation of Biomarker Candidate Molecules in Laryngeal CarcinomaLarynx CancerLarynx Carcinoma
NCT05217147Hacettepe University80